New York, USA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight The BRAF Inhibitors market is expected ...

Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the ...

The three-drug regimen – based on Array BioPharma/Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) along with Eli Lilly’s EGFR-targeted antibody E ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall survival in a late-stage colorectal cancer (CRC) study.

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its oncology drug, Braftovi (encorafenib), for treating patients with ...

Doctors use targeted cancer drugs or immunotherapy to treat melanoma that has spread elsewhere in the body such as the liver, lungs or bone (advanced cancer). Or to treat stage 3 melanoma that cannot ...

In patients with metastatic colorectal cancer harboring a BRAF V600E mutation, the combo not only staved off disease progression but it also significantly extended patients’ lives compared with ...